. The Authors reported that glucagon responses to mixed meal test were not impaired in patients with fulminant type 1 diabetes whose diabetes duration was >4 years. We evaluated glucagon responses to arginine stimulation in five patients with fulminant type 1 diabetes, and those in five age-and diabetes duration-matched patients with acute-onset type 1 diabetes who were enrolled in our study 3 (their age and diabetes duration were 54.8 -20.9 vs 55.6 -18.1 years and 3.0 -6.3 vs 3.2 -6.9 years, respectively; data were presented as mean -standard deviation). As shown in Figure 1 , the curves of glucagon levels were similar between the two groups. Another 44-year-old woman underwent an arginine stimulation test at the onset of fulminant type 1 diabetes and 11 months later, and her glucagon response did not decrease (her glucagon levels at pre-loading, at peak and the area under the curve of the glucagon were; 139 vs 204 pg/mL, 406 vs 425 pg/mL and 3.7 9 10 4 vs 4.6 9 10 4 pg/mL/min at the onset of diabetes and 11 months later, respectively). On the contrary, another study reported that immunohistochemically stained glucagon-positive cell areas in the pancreas of patients with fulminant type 1 diabetes were significantly lower than those with autoimmune type 1 diabetes for short duration of 2.8 -1.9 months after the onset of diabetes 4 . The change in pancreatic a-cell Medical Labo, Tokyo, Japan; the intra-and interassay coefficients of variation were <20 and <15%, respectively). Dashed lines with squares show glucagon levels measured by enzyme-linked immunosorbent assay (ELISA; Mercodia AB, Sweden; the intra-and interassay coefficients of variation were 7.3-9.4% and 7.5-8.5%, respectively). Patients were enrolled in our study 3 . Variables are presented as mean -standard deviation. function might be heterogenous among patients with fulminant type 1 diabetes.
Regarding the methods to measure the glucagon level, Murase-Mishiba et al. used conventional radioimmunoassay (RIA). In our case report, we measured the glucagon levels by not only RIA, but also with quantitative sandwich enzyme-linked immunosorbent assays (ELISA), and the curves of the glucagon levels were similar. We also measured the glucagon levels of patients with fulminant and acute-onset type 1 diabetes by ELISA, as shown in Figure 1 . Their glucagon levels measured by RIA and ELISA were similar. However, a recent study showed that the trend of glucagon response to a mixed meal test measured by RIA was different from that measured by ELISA and novel liquid chromatography-high resolution mass spectroscopy, which can measure the glucagon levels more specifically 5 . Further prospective, long-term longitudinal studies with large numbers of patients are warranted to gain a complete understanding of the pancreatic a-cell function in fulminant type 1 diabetes. 
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